Bridging Innovation & Scale

Engineering Success for
Global Healthcare Ventures

We provide end-to-end market entry execution for founders entering India and deep-tech de-risking strategies for Venture Capital & Family Offices.

For Founders: Enter India For Investors: Portfolio Advisory
Dr. Sachin Malhotra

Dr. Sachin Malhotra

Founder & CEO, Gentrac Labs

About The Founder

Scientist-CEO. Operator. Strategist.

With 22 years of "bench-to-bedside" experience, Dr. Malhotra specializes in bridging the gap between deep-tech innovation and commercial scale. From conducting translational research at Harvard Medical/BIDMC to scaling digital health ecosystems for 350,000+ clinicians.

Proven Scale: Built a diagnostic chain to 20% market share and scaled Tech Care for All to a dominant Pan-India player.

Regulatory Mastery: Experience navigating US-FDA and Indian CDSCO landscapes, including resolving FDA holds.

Global Lens: A career spanning the US, India, and Africa, orchestrating GTM for giants like Pfizer, BMS, and Medtronic.

For Founders

India Market Entry & Scaling

We provide a turnkey "Landing Pad" for Medical Device, Pharma, and HealthTech companies entering the Indian market.

Market Strategy

Deep-dive research and GTM strategy tailored to India's ecosystem.

Regulatory & Clinical

Navigating CDSCO/DCGI approvals and clinical trial design.

Setup & Compliance

Incorporation, legal entity setup, and tax structuring.

Leadership Hiring

Recruiting high-integrity operators for your local leadership.

For Investors

De-Risking Portfolios.

Scientific & Operational Due Diligence that financial models often miss.

Technical Due Diligence

Validating the "scientific truth" and biomarkers.

The "Polymath Lens"

  • Bench-to-Bedside Translation
  • Cross-Border Arbitrage
Request a Portfolio Audit

Start the Conversation

Whether you are a founder or an investor, let's discuss how we can engineer success.

Message Sent!

Thank you, we'll get back to you shortly.

sachin@gentraclabs.com
New Delhi, India
LinkedIn Profile